New York
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in New York: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
New York follows the federal interpretation in assessing the patentability of naturally occurring genes and whether isolating a gene constitutes an invention. The state's courts are bound by federal precedent but may also consider the implications of state law in biotechnology and patent law.
In New York, similar to federal law, naturally occurring sequences of genes cannot be patented; however, specific methods and applications derived from such natural products may be patentable if they meet the necessary criteria for non-obviousness and usefulness.
The court reinforced that patent eligibility must align with federal standards, particularly concerning natural products and their alterations.
The court focused on the patentability of naturally occurring discoveries and established that significant modification or application is necessary for patent eligibility.
Addressed regulatory implications of patents in biotechnological innovations and reaffirmed the need for federal compliance in assessing a patent's validity.
New York's approach is largely consistent with the federal stance articulated in Association for Molecular Pathology v. Myriad Genetics, Inc., which holds that naturally occurring DNA sequences are not patentable. However, New York courts may emphasize the practical implications of patent applications in state regulations pertaining to biotechnology.
The principles from this case are relevant for the New York bar exam, especially in topics around patent eligibility and biotechnology, as well as understanding the interface between state and federal law.